Skip to main content
Premium Trial:

Request an Annual Quote

Compugen s Q3 Revenues Slide As Company Refocuses; CEO to Step Down in 2005

NEW YORK, Nov. 1 (GenomeWeb News) - Compugen yesterday reported sliding revenues and increased losses for the third quarter, resulting from the discontinuation of certain products tied to the company's new focus on diagnostics and drug discovery.

In addition, the company's president and CEO, Mor Amitai, said he will step down by the end of next year. Amitai said is stepping down so that Compugen may hire a CEO with "more experience in pharmaceutical product development and commercialization."


Compugen booked $1 million in revenues for the quarter ended Sept. 30, down from $2 million during the same period last year.


R&D expenses decreased slightly to $2.8 million, from $3.1 million during the same quarter in 2003.


The company's net loss widened to $3.6 million, or $.13 per share, from $3.2 million, or $.12 per share, during the year-ago quarter.


"These results reflect the implementation of the company's previously announced decision to focus on diagnostic and therapeutic discovery and related intellectual property based commercialized and alliances," Compugen said in a statement.


As of Sept. 30, Compugen had $25 million in cash, cash equivalents, short-term cash deposits, and short-term marketable securities.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.